MedTrace Logo

Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

NCT01474174 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2018-07-03

No results posted yet for this study

Summary

This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for CNS tumors

Conditions

  • Central Nervous System Neoplasm

Interventions

BIOLOGICAL

trivalent influenza vaccine

Given IM

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Glenn Lesser · Wake Forest University Health Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01474174 on ClinicalTrials.gov